Skip to content

G&A at other companies

Axogen logo
AxogenAXGN
$12.87M+36.1%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$9.4M+54.9%

Other financials

Income statement

See full
Revenue$66.6M+11.2%
Gross profit$48.4M+16.8%
Operating income$17.8M+40.8%
Net income$15.7M+42.4%
EPS (diluted)$0.68+41.7%

Balance sheet

See full
Cash & equivalents$26.9M+6.0%
Total debt$20.9M+20.6%
Total equity$406.6M+17.0%
Total assets$629.5M+13.2%

Cash flow

See full
Operating cash flow$15.1M+67.0%
CapEx$2.8M+101%
Free cash flow$12.3M+60.8%

Valuation

See full
Market cap$2.1B+31.4%
Enterprise value$2.1B+31.6%
P/E33.7×-1.7×
P/S8.2×+1.1×

Profitability

See full
Gross margin72.4%+3.6pp
Operating margin28.5%+5.1pp
Net margin24.3%+4.4pp
FCF margin30.9%+12.7pp

Returns & leverage

See full
Return on equity16.5%+2.8pp
Debt / equity0.1×0.0×
Current ratio14.3×-2.2×

Where this comes from

Reported directly by LeMaitre Vascular in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: LeMaitre Vascular’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LeMaitre Vascular's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LeMaitre Vascular's G&A?
LeMaitre Vascular (LMAT) reported G&A of $12.05M in Q1 2026.
How has LeMaitre Vascular's G&A changed year-over-year?
LeMaitre Vascular's G&A increased by 14.9% year-over-year, from $10.49M to $12.05M.
What is the long-term trend for LeMaitre Vascular's G&A?
Over 4 years (2021 to 2025), LeMaitre Vascular's G&A has grown at a 13.3% compound annual growth rate (CAGR), from $25.5M to $42.02M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.